The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
This survey of members of the Association of the British Pharmaceutical Industry (ABPI) was conducted online between 23 – 28 March 2017, with 32 out of 58 members responding.
When asked about the impact of the introduction of a new £20m Budget Impact Test:
When asked about the impact of changes to the Highly Specialised Treatments programme:
When asked about the impact of a new £20m Budget Impact Test and changes to the Highly Specialised Treatments programme: